Prothena Corporation

Prothena Corporation Net Tangible Assets

The Net Tangible Assets of Prothena Corporation (PRTA) as of Nov 17, 2026 is 280.47 M USD. In the previous year, Net Tangible Assets was 486.93 M USD — a change of -42.40% (lower).

Net Tangible Assets

280.47 MUSD

YoY

-42.40%

Last updated:

Net Tangible Assets of Prothena Corporation is 2025 280.47 M USD. Net Tangible Assets of Prothena Corporation was 2024 486.93 M USD. It decreases by -42.40% lower compared to the previous year.

The Prothena Corporation Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
323.00 M USD
Jan 1, 2019
272.92 M USD
Jan 1, 2020
184.01 M USD
Jan 1, 2021
466.04 M USD
Jan 1, 2022
622.04 M USD
Jan 1, 2023
561.37 M USD
Jan 1, 2024
486.93 M USD
Jan 1, 2025
280.47 M USD
The Prothena Corporation Net Tangible Assets history
YEARNet Tangible AssetsYoY
280.47 MUSD-42.40%
486.93 MUSD-13.26%
561.37 MUSD-9.75%
622.04 MUSD+33.47%
466.04 MUSD+153.28%
184.01 MUSD-32.58%
272.92 MUSD-15.50%
323.00 MUSD-20.68%
407.19 MUSD+11.44%
365.40 MUSD+1.31%
360.67 MUSD+24.42%
289.89 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prothena Corporation stock

Net Tangible Assets of Prothena Corporation is 280.47 M USD in 2025.

Net Tangible Assets of Prothena Corporation changed from 486.93 M USD to 280.47 M USD, representing a -42.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Prothena Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Prothena Corporation

All Key Metrics — Prothena Corporation